Osteopenia-osteoporosis syndrome in patients with thalassemia: Understanding of type of bone disease and response to treatment

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Chatterjee, Ratna ^a   Bajoria, Rekha ^a,b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bone markers; Dexa scan; Histomorphometry; HRT; Hypogonadotrophic hypogonadism; Osteopenia?osteoporosis syndrome; Pamidronate; Thalassemia

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; PAMIDRONIC ACID;

BETA THALASSEMIA; BONE BIOPSY; BONE DISEASE; BONE PAIN; BONE TURNOVER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; LUMBAR SPINE; MALE; MORBIDITY; MORPHOMETRICS; OSTEOPENIA; OSTEOPOROSIS; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; THALASSEMIA; TREATMENT RESPONSE;

ABSORPTIOMETRY, PHOTON; ANTI-INFLAMMATORY AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; OSTEOPOROSIS; THALASSEMIA; TREATMENT OUTCOME;

EID: 73949088213     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903347898     Document Type: Conference Paper

References (8)

1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010-2018, review.
2. Chatterjee RGM, Helal MA. Hypogonadism is a key contributor to the severity of osteoporosis in thalassaemic patients. 10th International Federation Conference (TIF) October 18-21; 2001.
3. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000;53(1):33-42.
4. Borgna-Pignatti C. Thalassemia. A few new tiles in a large mosaic. Haematologica. 2006;91(9):1159-1161, review.
5. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol.2002;32:492-497.
6. Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19:722-727.
7. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123:730-737.
8. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int. 2001;12:570-575.